Regeneron and Eli Lilly are now asking regulators to expand authorization on their antibody treatments just one day after promising new research was released.

Right now both companies produce treatments that have been approved for emergency use in mild or moderate COVID-19 cases.

But as News 12 has reported, this new research shows that these treatments can significantly reduce the risk of infection, hospitalization, and death in high risk cases.

Regulators say they are holding off on a decision until more research is done.